Riska H, Stenius-Aaniala B, Sovijärvi A R
Department of Pulmonary Medicine, University of Helsinki, 00290 Helsinki, Finland.
Postgrad Med J. 1986;62 Suppl 1:52-3.
A series of 8 adult patients with stable bronchial asthma and an established diagnois of essential hypertension (WHO I and II) was studied in a randomized double-blind cross-over study to assess the effect of captopril (50-100 mg/day) and verapamil (160-240 mg/day) on blood pressure, lung function and asthmatic symptoms. The effect of the medication on blood pressure was significant with a mean of 137/86 mmHg and 148/90 mmHg after 4 weeks on captopril and verapamil, respectively, with fewer orthostatic changes caused by captopril. There were no marked changes of asthmatic symptoms or peak expiratory flow (PEF) measurements during the trial.
在一项随机双盲交叉研究中，对8例患有稳定型支气管哮喘且已确诊原发性高血压（世界卫生组织I级和II级）的成年患者进行了研究，以评估卡托普利（50 - 100毫克/天）和维拉帕米（160 - 240毫克/天）对血压、肺功能和哮喘症状的影响。用药后对血压的影响显著，服用卡托普利和维拉帕米4周后，平均血压分别为137/86毫米汞柱和148/90毫米汞柱，卡托普利引起的体位性变化较少。试验期间哮喘症状或呼气峰值流速（PEF）测量值无明显变化。
